Literature DB >> 15012917

Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure.

Taketoshi Yamazaki1, Jong-Dae Lee, Hiromasa Shimizu, Hiroyasu Uzui, Takanori Ueda.   

Abstract

BACKGROUND AND AIMS: It has been reported that matrix metalloproteinase (MMP) protein concentration and activity are upregulated in the failing human heart. However, there are few reports describing the role of elevated level of circulating MMPs in congestive heart failure (CHF) patients. This study examined whether circulating matrix metalloproteinases (MMPs) are also related to the pathogenesis of CHF.
METHODS: We measured circulating levels of matrix metalloproteinase-2 (MMP-2) in 52 patients with CHF (left ventricular ejection fraction (LVEF) <50%). The patients were also subdivided into two groups according to NYHA functional class; mild CHF (class II, n=43) and severe CHF (class III, n=9).
RESULTS: The serum level of MMP-2 and MMP-2/TIMP-2 ratio were significantly higher in CHF than in controls (P<0.01). Among patient groups, serum levels of MMP-2 were significantly higher in patients with severe CHF than in patients with mild CHF (P<0.01). Plasma levels of BNP had a significant positive correlation with circulating levels of MMP-2 (r=0.78; P<0.01) and MMP-2/TIMP-2 ratio (r=0.60; P<0.01).
CONCLUSIONS: Our data showed that the circulating MMP-2 concentration was increased in CHF patients and that the levels were related to the plasma levels of BNP in CHF, suggesting that the elevated levels are related to developing heart failure syndrome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15012917     DOI: 10.1016/j.ejheart.2003.05.002

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  20 in total

1.  Biological variation of extracellular matrix biomarkers in patients with stable chronic heart failure.

Authors:  Tobias Täger; Clara Wiebalck; Hanna Fröhlich; Anna Corletto; Hugo A Katus; Lutz Frankenstein
Journal:  Clin Res Cardiol       Date:  2017-08-04       Impact factor: 5.460

2.  Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and heart failure outcomes.

Authors:  Vikas Bhalla; Vasiliki V Georgiopoulou; Ali A Azeem; Catherine N Marti; Robert T Cole; Sonjoy R Laskar; Christine De Staercke; W Craig Hooper; Andrew L Smith; Andreas P Kalogeropoulos; Javed Butler
Journal:  Int J Cardiol       Date:  2011-07-01       Impact factor: 4.164

3.  The relationship between aminoterminal propeptide of type III procollagen and heart rate variability parameters in heart failure patients: a potential serum marker to evaluate cardiac autonomic control and sudden cardiac death.

Authors:  Yen-Hung Lin; Chen Lin; Men-Tzung Lo; Hung-Ju Lin; Yen-Wen Wu; Ron-Bin Hsu; Chia-Lun Chao; Hsiu-Ching Hsu; Pa-Chun Wang; Vin-Cent Wu; Shoei-Shen Wang; Chi-Ming Lee; Kuo-Liong Chien; Yi-Lwun Ho; Ming-Fong Chen; Chung-Kang Peng
Journal:  Clin Chem Lab Med       Date:  2010-09-17       Impact factor: 3.694

4.  Changes in collagen metabolism account for ventricular functional recovery following beta-blocker therapy in patients with chronic heart failure.

Authors:  Miho Fukui; Akiko Goda; Kazuo Komamura; Ayumi Nakabo; Mitsuru Masaki; Chikako Yoshida; Shinichi Hirotani; Masaaki Lee-Kawabata; Takeshi Tsujino; Toshiaki Mano; Tohru Masuyama
Journal:  Heart Vessels       Date:  2014-10-29       Impact factor: 2.037

5.  Optimized ventricular restraint therapy: adjustable restraint is superior to standard restraint in an ovine model of ischemic cardiomyopathy.

Authors:  Lawrence S Lee; Ravi K Ghanta; Suyog A Mokashi; Otavio Coelho-Filho; Raymond Y Kwong; Michael Kwon; Jian Guan; Ronglih Liao; Frederick Y Chen
Journal:  J Thorac Cardiovasc Surg       Date:  2012-06-12       Impact factor: 5.209

6.  Relationships between sodium levels, haemodynamics and metalloproteinases in heart failure patients.

Authors:  Tetsuji Morishita; Hiroyasu Uzui; Kaori Hisazaki; Yasuhiko Mitsuke; Taketoshi Yamazaki; Hiroshi Tada
Journal:  Heart Vessels       Date:  2022-01-15       Impact factor: 2.037

7.  Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction.

Authors:  Hui-Zhong Zhou; Xiaokui Ma; Mary O Gray; Bo-qing Zhu; Anita P Nguyen; Anthony J Baker; Ursula Simonis; Gary Cecchini; David H Lovett; Joel S Karliner
Journal:  Biochem Biophys Res Commun       Date:  2007-04-23       Impact factor: 3.575

8.  Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure.

Authors:  Andrew T Yan; Raymond T Yan; Francis G Spinale; Rizwan Afzal; Himali R Gunasinghe; Robert E Stroud; Robert S McKelvie; Peter P Liu
Journal:  Eur J Heart Fail       Date:  2008-01-29       Impact factor: 15.534

9.  Pheochromocytoma-induced cardiomyopathy is modulated by the synergistic effects of cell-secreted factors.

Authors:  Hector R Mobine; Aaron B Baker; Libin Wang; Hiroko Wakimoto; Kurt C Jacobsen; Christine E Seidman; J G Seidman; Elazer R Edelman
Journal:  Circ Heart Fail       Date:  2009-02-10       Impact factor: 8.790

10.  A novel intracellular isoform of matrix metalloproteinase-2 induced by oxidative stress activates innate immunity.

Authors:  David H Lovett; Rajeev Mahimkar; Robert L Raffai; Leslie Cape; Elena Maklashina; Gary Cecchini; Joel S Karliner
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.